Enhanced Methods for Preparing Phospholipid-Based Ultrasound Contrast Agents with Improved Stability

This inventive concept introduces novel methods and systems for preparing phospholipid-based ultrasound contrast agents with enhanced stability, by reducing divalent metal cation concentrations and introducing chelating agents, resulting in improved imaging quality and reduced artifacts.

The original patent disclosed methods for preparing phospholipid-based ultrasound contrast agents, but it was limited by the susceptibility of certain phospholipid-based formulations to divalent metal cations, which can affect the stability and efficacy of the contrast agents. This inventive concept addresses these limitations by introducing novel methods and systems to mitigate the impact of divalent metal cations.

The inventive concept comprises a system for preparing phospholipid-based ultrasound contrast agents, which includes a calcium-removing module to reduce the concentration of divalent metal cations in a phospholipid solution, and a microsphere-forming module to encapsulate gas microspheres with the phospholipid solution. Additionally, the inventive concept introduces a method for enhancing the stability of lipid-encapsulated gas microspheres by introducing a chelating agent to a phospholipid solution to bind divalent metal cations, and then forming microspheres with the phospholipid solution. The inventive concept also includes a lipid-encapsulated gas microsphere composition with a reduced concentration of divalent metal cations, and a system for real-time monitoring of divalent metal cation concentrations in a phospholipid solution.

The new claims introduce novel and non-obvious solutions to the problem of divalent metal cation susceptibility in phospholipid-based ultrasound contrast agents. The use of calcium-removing modules, chelating agents, and real-time monitoring systems to mitigate the impact of divalent metal cations is a significant departure from the original patent and provides a substantial improvement in the stability and efficacy of the contrast agents.

Alternative embodiments of the inventive concept could include the use of different types of chelating agents, varying concentrations of divalent metal cations, and different methods for removing calcium and magnesium ions from the phospholipid solution. Additionally, the inventive concept could be adapted for use with different types of ultrasound contrast agents, such as those based on liposomes or nanoparticles.

The inventive concept has significant commercial potential in the medical imaging industry, particularly in the field of ultrasound imaging. The improved stability and efficacy of the contrast agents could lead to better image quality, reduced artifacts, and improved patient outcomes. The target market for this inventive concept includes medical imaging companies, hospitals, and research institutions.